The Readout

The Readout By Meghana Keshavan

Sarepta’s gene therapy disappoints, beyond vaccines for mRNA, & what a Democratic Senate means for biotech

The Readout By Damian Garde

A biotech rainmaker returns, Slaoui sticks around, & Pfizer edges ahead of Sarepta

The Readout By Damian Garde

Biotech’s inaugural 2021 IPOs, Mukherjee’s new startup, & how the FDA can extend Warp Speed

The Readout By Damian Garde

Biotech’s big Q1 news, Pfizer’s CMO changeover, & annual price hikes

The Readout By Meghana Keshavan

The biotech 2021 preview, Pfizer to offer vaccine to placebo arm earlier, & a half dose of Moderna?

The Readout By Damian Garde

2020’s winning biotech VCs, UniQure’s safety alarm, & naming Moderna’s Covid-19 vaccine

The Readout By Meghana Keshavan

Agios sells cancer arm, a disguised Novartis blessing, & a former FDA chief rises again

The Readout By Meghana Keshavan

Moderna on track for EUA, J&J harassment allegations, & new antibodies tested for Covid-19

The Readout By Damian Garde

Moderna’s big vaccine review, a diabetes drug for Alzheimer’s, & Trump’s loudest drug pricing opponent

The Readout By Damian Garde

2020’s worst biotech CEOs, how Moderna’s vaccine compares to Pfizer’s, & Sage’s new CEO

The Readout By Damian Garde

2020’s best CEOs, Moderna’s Covid-19 data dump, & how to name a vaccine

The Readout By Meghana Keshavan

Let the vaccinations begin, AstraZeneca’s acquisition, & regulatory M&A

The Readout By Meghana Keshavan

Sanofi’s stalled vaccine, Pfizer’s ad comm dissected, & condensate therapy

The Readout By Damian Garde

How to watch Pfizer’s big vaccine test, J&J’s downsized study, & a press release worth $1 billion

The Readout By Damian Garde

FDA endorses Pfizer’s Covid-19 vaccine, Vioxx gets closer to a return, & AstraZeneca’s data are still confusing

The Readout By Damian Garde

A guide to Pfizer’s vaccine data dump, the CEOs standing up Trump, & diverging data in sickle cell disease

The Readout By Meghana Keshavan

Sanguine ASH data, a remdesivir tax payout, & the reality of 20 million

The Readout By Meghana Keshavan

Cytokine storms explained, on ending pharma gifts, & vaccines for the elderly

The Readout By Damian Garde

What to watch for at ASH, Lilly’s Covid-19 revenue clears $1 billion, & Moderna pads rivals’ pockets

The Readout By Damian Garde

Ovid’s lead drug fails, Trump schedules a vaccine summit, & nanotech’s big moment

The Readout By Damian Garde

Moderna is worth more than Vertex, Google wins a biology bake off, & Regeneron looks to gene therapy for Covid-19

The Readout By Meghana Keshavan

New Moderna data, Biogen bets on Sage, & CAR-T logistics

The Readout By Damian Garde

Covid-19 could change trials forever, vaccines might not be lucrative long term, & Alnylam’s five-year journey

The Readout By Damian Garde

AstraZeneca’s puzzling vaccine data, another Covid-19 IPO, & the end of a 14-year scientific saga

The Readout By Meghana Keshavan

Most Read

IPO anticlimax, Covid-19 vaccine questions, and a new prion approach

Pfizer’s 95% vaccine efficacy, disappointment in ALS, & FDA promises of transparency

Covid-19 vaccine data from Novavax & the future of peanut allergy treatment

Another blow to the amyloid theory & Covid-19 testing troubles

The year in biotech SPACs, AstraZeneca vs. Regeneron, & CRISPR gets $5 billion richer

A patent blow for Moderna, loosened Covid-19 regs, & the truth about inactive ingredients

The saga of a ‘criminal’ short report, Moderna’s valuation, & UniQure’s patents

Pfizer/BioNTech’s second vaccine, hemophilia advocates relieved, & is FDA more strict?

All Coverage

Sarepta’s gene therapy disappoints, beyond vaccines for mRNA, & what a Democratic Senate means for biotech

A biotech rainmaker returns, Slaoui sticks around, & Pfizer edges ahead of Sarepta

Biotech’s inaugural 2021 IPOs, Mukherjee’s new startup, & how the FDA can extend Warp Speed

Biotech’s big Q1 news, Pfizer’s CMO changeover, & annual price hikes

The biotech 2021 preview, Pfizer to offer vaccine to placebo arm earlier, & a half dose of Moderna?

2020’s winning biotech VCs, UniQure’s safety alarm, & naming Moderna’s Covid-19 vaccine

Agios sells cancer arm, a disguised Novartis blessing, & a former FDA chief rises again

Moderna on track for EUA, J&J harassment allegations, & new antibodies tested for Covid-19

Moderna’s big vaccine review, a diabetes drug for Alzheimer’s, & Trump’s loudest drug pricing opponent

2020’s worst biotech CEOs, how Moderna’s vaccine compares to Pfizer’s, & Sage’s new CEO

2020’s best CEOs, Moderna’s Covid-19 data dump, & how to name a vaccine

Let the vaccinations begin, AstraZeneca’s acquisition, & regulatory M&A

Sanofi’s stalled vaccine, Pfizer’s ad comm dissected, & condensate therapy

How to watch Pfizer’s big vaccine test, J&J’s downsized study, & a press release worth $1 billion

FDA endorses Pfizer’s Covid-19 vaccine, Vioxx gets closer to a return, & AstraZeneca’s data are still confusing

A guide to Pfizer’s vaccine data dump, the CEOs standing up Trump, & diverging data in sickle cell disease

Sanguine ASH data, a remdesivir tax payout, & the reality of 20 million

Cytokine storms explained, on ending pharma gifts, & vaccines for the elderly

What to watch for at ASH, Lilly’s Covid-19 revenue clears $1 billion, & Moderna pads rivals’ pockets

Ovid’s lead drug fails, Trump schedules a vaccine summit, & nanotech’s big moment

Moderna is worth more than Vertex, Google wins a biology bake off, & Regeneron looks to gene therapy for Covid-19

New Moderna data, Biogen bets on Sage, & CAR-T logistics

Covid-19 could change trials forever, vaccines might not be lucrative long term, & Alnylam’s five-year journey

AstraZeneca’s puzzling vaccine data, another Covid-19 IPO, & the end of a 14-year scientific saga

A third Covid-19 vaccine is effective & Resilience launches with $800M